You searched for "invasive"

410 results found

Penile cancer

Case 1 A 67-year-old man presents with a worsening red patch over the past three months. It looks velvety in some areas. What is the most likely diagnosis? What are the risk factors? How do you classify this condition? How...

The cost of bladder cancer: what can be done?

The rising cost of cancer care is a growing concern for health systems. A 2020 study estimated Europe’s annual cancer-related expenditure at €199 billion, with €109 billion attributed to healthcare costs. Bladder cancer (BC), in particular, imposes a significant financial...

Urodynamics – A quick pocket guide

This is an absolute requisite of a book for anyone in urology whatever their stage of development. For the experienced it provides some useful teaching tips and for the beginner even a cursory read will make you feel like a...

Reducing the burden of NMIBC: outpatient laser management in morbid patients

With non-muscle invasive bladder cancer (NMIBC) posing a significant burden on urological departments, alternative ways of safely and effectively managing these patients with a minimally invasive approach is desirable. As rates of recurrence are high but progression rates low, and...

15th Emirates International Urological Conference 2026

This special anniversary edition will feature a comprehensive and forward looking scientific program encompassing the full spectrum of urology specialties and sub specialties, including robotic and minimally invasive urology, urological oncology, endourology and stone disease, functional and reconstructive urology, female...

RSM: Urothelial cancer: advances, innovation and improving outcomes

Why attend? Hear from leading experts including Professor Param Mariappan, Professor Tom Powles, Professor Ben Challacombe and Professor Alison Birtle Explore how quality improvement initiatives, including lessons from Scotland's bladder cancer KPI programme, are shaping care delivery. Gain updates on...

Penile cancer: a practical approach

Penile cancer is rare and accounts for less than 1% of all new cancer cases in males in the UK, with around 640 new cases diagnosed every year [1]. In England and Wales, the annual incidence is between 1.2 and...

Molecular biology – bladder cancer

Background Bladder cancer is the most common cancer of the urinary tract and approximately 90% of bladder cancers diagnosed in North America and Europe are transitional cell carcinomas (TCC). For the purposes of diagnosis and treatment, bladder cancer is often...

COVID-19 and acute kidney injury

Newspapers and online media are full of the effects of the coronavirus on airways and olfactory functions and the importance of respiratory physicians (pulmonologists in the USA), ventilators and intensive care teams. However, as per the Intensive Care National Audit...

Uropathology: what’s the diagnosis?

Case 1 A 28-year-old man presented with a left testicular mass. Tumour markers were taken and he went on to have a radical inguinal orchidectomy. The specimen and histology are shown. Which testicular tumour markers were taken? What does their...

ABU joins BCG in fight against NMIBC recurrence?

The authors test a hypothesis retrospectively in two cohorts of patients with non-muscle invasive bladder cancer (NMIBC), that endogenous bacteria in the bladder might exert antitumour effects, similar to live mycobacteria (BCG), through local immune-related or other mechanisms, on NMIBC...

Comparing intravesical chemohyperthermia with Mitomycin C versus BCG in treating bladder cancer

In the advent of the recent Bacillus Calmette–Guérin (BCG) crisis, the importance of alternative adjuvant treatments for intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) has been highlighted. Chemohyperthermia (CHT) has emerged as an option, however there remains a lack of...